Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PKM2 siRNA
- Development stage
- Unknown
- Lead developer
- University of Virginia
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
PKM2 siRNA is a small interfering RNA designed to silence the expression of Pyruvate Kinase M2 (PKM2), an isoenzyme of pyruvate kinase that is frequently overexpressed in cancer cells and plays a critical role in the Warburg effect (aerobic glycolysis). By targeting PKM2 mRNA for degradation via the RNA interference (RNAi) pathway, this siRNA reduces PKM2 protein levels, leading to decreased metabolic activity, reduced ATP and glutathione levels, and the activation of AMP-activated protein kinase (AMPK). In preclinical studies, particularly in glioblastoma and glioma stem cells, PKM2 knockdown has been shown to inhibit cell growth and invasion while inducing apoptosis, with minimal toxicity observed in normal astrocytes.
- Other names
- pyruvate kinase M2 siRNAPKM2 small interfering RNAPKM-2 small interfering RNAPKM 2 small interfering RNA
02
Targets
PKM2 (Pyruvate kinase M2 isoform)Pyruvate kinase muscle isozyme 2 messenger RNA
Beyond the preview
Go deeper on PKM2 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PKM2 siRNA.